Given the recent general election, it is no surprise that vacancies dropped in June. With Businesses waiting on the outcome of the election, whilst Labour winning was a given, the coming weeks will now see a blitz of policy announcements, which will give greater clarity when it comes to investment.
Is it the responsibility of Government to directly stimulate economic growth, or is it for them to create the environment where businesses invest themselves? Statism, or interventionist supply side policies are coming to the fore once more, and for the incoming Labour Government, there are a myriad of policy proposals designed to achieve growth.
For the UK, Financial Services has a critical part to play, in terms of GDP, our balance of payments and employment. Within the Financial Services industry though, increasingly Fintech is starting to come to the fore. New challengers such as Starling, Monzo, Revolut and Wise have disrupted the incumbents and as a result, the industry has permanently changed.
The impact of the budget on tax recruitment is apparent. March 2024 was the record month for tax vacancies going back to January 2019, beating even the peak post pandemic months in 2021. At the same time, in a recent report featured in Bloomberg, the UK is set to see 9,500 millionaires repatriate away, which is more than any other country globally, with the exception of China.
With the general election looming, increasingly the question is becoming one of judgement. Who do we trust to represent the country and with that, the economy? The UK economy is consumption led, meaning that what happens in retail and consumer goods and services, is significant, when looking at economic activity. With that, in what is turning out to be a spectacular own goal, the Government’s ill fated ‘tourist tax’ on retail (not allowing VAT rebates on shopping) is starting to be felt amongst retailers.
For the UK Pharmaceuticals industry, the headwinds are real. The post pandemic hangover, at first caused by clinical trials being delayed on approval, so that COVID-19 related drugs could be prioritised meant that as the pandemic subsided, the pipeline of other drugs going to clinical trials had slowed to a trickle. The MHRA was supposedly tasked with creating a fast track regime to overcome this, equally even now, the EMA is approving drugs faster. Hence for pharmaceuticals companies looking at where they should organise trials, the UK is as a result, less attractive.
